Verzijl H T, van Engelen B G, Luyten J A, Steenbergen G C, van den Heuvel L P, ter Laak H J, Padberg G W, Wevers R A
Department of Neurology, University Hospital Nijmegen, The Netherlands.
Ann Neurol. 1998 Jul;44(1):140-3. doi: 10.1002/ana.410440124.
Two types of myoadenylate deaminase (MAD) deficiency have been described, primary or inherited, and secondary or acquired MAD deficiency. In this study, we investigated whether secondary MAD deficiency is indeed acquired or merely coincidental. We demonstrated the same underlying molecular defect, a C34T transition, in both types of deficiency. Furthermore, the same frequency of the mutant MAD allele was found in the general population as in patients with neuromuscular complaints. We therefore conclude that in the Dutch population, secondary MAD deficiency is merely a "coincidental" finding, and that MAD deficiency is a harmless genetic variant.
已描述了两种类型的肌腺苷酸脱氨酶(MAD)缺乏症,即原发性或遗传性MAD缺乏症以及继发性或后天性MAD缺乏症。在本研究中,我们调查了继发性MAD缺乏症是否确实是后天获得的,还是仅仅是巧合。我们在两种类型的缺乏症中都证实了相同的潜在分子缺陷,即C34T转换。此外,在普通人群中发现的突变MAD等位基因频率与有神经肌肉症状的患者相同。因此,我们得出结论,在荷兰人群中,继发性MAD缺乏症仅仅是一个“巧合”的发现,并且MAD缺乏症是一种无害的基因变异。